A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients. METHODS: In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependent β-thalassemia to receive best supportive care plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least 48 weeks. The primary end point was the percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval. Other efficacy end points included reductions in the transfusion burden during any 12-week interval and results of iron studies. RESULTS: A total of 224 patients were assigned to the luspatercept group and 112 to the placebo group. Luspatercept or placebo was administered for a median of approximately 64 weeks in both groups. The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P<0.001). During any 12-week interval, the percentage of patients who had a reduction in transfusion burden of at least 33% was greater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the percentage of those who had a reduction of at least 50% (40.2% vs. 6.3%). The least-squares mean difference between the groups in serum ferritin levels at week 48 was -348 μg per liter (95% confidence interval, -517 to -179) in favor of luspatercept. Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more common with luspatercept than placebo. CONCLUSIONS: The percentage of patients with transfusion-dependent β-thalassemia who had a reduction in transfusion burden was significantly greater in the luspatercept group than in the placebo group, and few adverse events led to the discontinuation of treatment. (Funded by Celgene and Acceleron Pharma; BELIEVE ClinicalTrials.gov number, NCT02604433; EudraCT number, 2015-003224-31.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
Citations
Cites
Global epidemiology of haemoglobin disorders and derived service indicators
Modell, B. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.06.036673 · Cited by 1,924
Borgna‐Pignatti, C., Rugolotto, S., Stefano, P. D., Zhao, H., Cappellini, M. D., Vecchio, G. C. D., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., et al. (2004) · PubMed · Cited by 1,119
Self-citationWood, J. C., Enriquez, C., Ghugre, N., Tyzka, J. M., Carson, S., Nelson, M. D., & Coates, T. D. (2005) · Blood · doi:10.1182/blood-2004-10-3982 · Cited by 1,045
Self-citationNoninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance
St. Pierre, T. G., Clark, P. R., Chua-anusorn, W., Fleming, A. J., Jeffrey, G. P., Olynyk, J. K., Pootrakul, P., Robins, E., & Lindeman, R. (2005) · Blood · doi:10.1182/blood-2004-01-0177 · Cited by 909
The inherited diseases of hemoglobin are an emerging global health burden
Weatherall, D. J. (2010) · Blood · doi:10.1182/blood-2010-01-251348 · Cited by 903
Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationSurvival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register
Modell, B., Khan, M., & Darlison, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02357-6 · Cited by 583
Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 445
Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.-S., El-Chafic, A.-H., Fasulo, M. R., & Cappellini, M. D. (2010) · Blood · doi:10.1182/blood-2009-09-243154 · Cited by 392
Self-citation
Cited by
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationTaher, A. T., Musallam, K. M., & Cappellini, M. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2021838 · Cited by 477
Self-citationFarmakis, D., Porter, J., Taher, A., Domenica Cappellini, M., Angastiniotis, M., Eleftheriou, A., & Taskforce, F. T. 2. T. G. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000732 · Cited by 307
Self-citationKattamis, A., Kwiatkowski, J. L., & Aydinok, Y. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00536-0 · Cited by 313
Self-citationPrimary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26857 · Cited by 305
Iron metabolism: pathophysiology and pharmacology
Roemhild, K., von Maltzahn, F., Weiskirchen, R., Knüchel, R., von Stillfried, S., & Lammers, T. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.05.001 · Cited by 302
“Therapeutics for iron deficiency conditions Iron supplement for oral administration Ferrous sulfate Iron salt Refills depleted iron stores Iron deficiency anemia Marketed NCT01904864 [28–32] Ferrous gluconate Iron salt Refills depleted iron stores Iron deficiency anemia Marketed NCT01528644 [28–32] Iron supplement for…”
BackgroundTuo, Y., Li, Y., Li, Y., Ma, J., Yang, X., Wu, S., Jin, J., & He, Z. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102619 · Cited by 283
“40 However, these novel treatments are still in development and pose new challenges in terms of safety, cost-effectiveness, and economic burden.”
BackgroundExagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Self-citationPlatzbecker, U., Della Porta, M. G., Santini, V., Zeidan, A. M., Komrokji, R. S., Shortt, J., Valcarcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I. S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00874-7 · Cited by 178
Self-citationTGF-beta signal transduction: biology, function and therapy for diseases
Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 174
China National Clinical Research Center for Respiratory Diseases, Shen, K.-L., National Center for Children’s Health, B., Group of Respirology, C. P. S., Chinese Medical Doctor Association Committee on Respirology Pediatrics, China Medicine Education Association Committee on Pediatrics, Chinese Research Hospital Association Committee on Pediatrics, China Non-government Medical Institutions Association Committee on Pediatrics, China Association of Traditional Chinese Medicine, C. O. C. H. A. M. R., China News of Drug Information Association, C. O. C. S. M., et al. (2020) · World Journal of Pediatrics · doi:10.1007/s12519-020-00362-4 · Cited by 166
Self-citationLong-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
Magrin, E., Semeraro, M., Hebert, N., Joseph, L., Magnani, A., Chalumeau, A., Gabrion, A., Roudaut, C., Marouene, J., Lefrère, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01650-w · Cited by 119
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
Motta, I., Bou‐Fakhredin, R., Taher, A. T., & Cappellini, M. D. (2020) · Drugs · doi:10.1007/s40265-020-01341-9 · Cited by 125
Self-citationΑlpha-thalassemia: A practical overview
Musallam, K. M., Cappellini, M. D., Coates, T. D., Kuo, K. H. M., Al-Samkari, H. T., Sheth, S., Viprakasit, V., & Taher, A. T. (2024) · Blood Reviews · doi:10.1016/j.blre.2023.101165 · Cited by 117
Self-citationIneffective erythropoiesis and its treatment
Cazzola, M. (2021) · Blood · doi:10.1182/blood.2021011045 · Cited by 125
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 101
Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?
Suh, J., & Lee, Y. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.3.151 · Cited by 104
“Based on the results of the phase 3 clinical trial conducted on patients with β-thalassemia, which demonstrated a significantly greater percentage of successful transfusion burden reductions in the luspatercept group than the placebo group,[92] ACE-536 was recently approved by the FDA for the treatment of anemia assoc…”
The role of CD71+ erythroid cells in the regulation of the immune response
Grzywa, T. M., Nowis, D., & Gołąb, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107927 · Cited by 84
Badawy, S. M., Beg, U., Liem, R. I., Chaudhury, S., & Thompson, A. A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002948 · Cited by 75
Self-citationDevelopment of luspatercept to treat ineffective erythropoiesis
Kubasch, A. S., Fenaux, P., & Platzbecker, U. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002177 · Cited by 85
Wetzlich, B., Nyakundi, B. B., & Yang, J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05120-y · Cited by 78
“Luspatercept began clinical trials in 2011 for the treatment of hematologic disorders and demonstrated efficacy in increasing hemoglobin counts in patients with anemia [64, 65], potentially attributed to a reduction in SMAD signaling leading to enhanced erythroid maturation [66].”
Taher, A. T., Cappellini, M. D., Kattamis, A., Voskaridou, E., Perrotta, S., Piga, A. G., Filosa, A., Porter, J. B., Coates, T. D., Forni, G. L., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00208-3 · Cited by 90
Self-citationZhang, H., Wang, A., Li, G., Zhai, Q., Huang, Z., Wang, X., Cao, Z., Liu, L., Liu, G., Chen, B., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.01.026 · Cited by 78
Metal Ion Signaling in Biomedicine
Rodriguez, R., Müller, S., Colombeau, L., Solier, S., Sindikubwabo, F., & Cañeque, T. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00577 · Cited by 76
Tefferi, A., Pardanani, A. D., & Gangat, N. (2023) · Haematologica · doi:10.3324/haematol.2022.282612 · Cited by 67
Principles of the activin receptor signaling pathway and its inhibition
Lodberg, A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.04.001 · Cited by 62
2021 update on clinical trials in β‐thalassemia
Musallam, K. M., Bou‐Fakhredin, R., Cappellini, M. D., & Taher, A. T. (2021) · American Journal of Hematology · doi:10.1002/ajh.26316 · Cited by 74
Self-citationThe use of luspatercept for thalassemia in adults
Cappellini, M. D., & Taher, A. T. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002725 · Cited by 62
Self-citationPorta, M. G. D., Garcia‐Manero, G., Santini, V., Zeidan, A. M., Komrokji, R. S., Shortt, J., Valcárcel, D., Jonasova, A. T., Dimicoli, S., Tiong, I. S., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00203-5 · Cited by 68
Self-citationIneffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs
Longo, F., Piolatto, A., Ferrero, G. B., & Piga, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137229 · Cited by 59
“Considering the safety profile, a higher risk of thromboembolic events was reported in these patients when treated with luspatercept, especially in the presence of other risk factors, such as splenectomy [66].”
BackgroundMethodSelf-citationChen, J., Zhu, W., Liu, J., Wang, G., Chen, X., Tan, Y., Xu, W., Qu, L.-W., Li, J., Yang, H.-J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00811-0 · Cited by 64
Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 54
Hokland, P., Daar, S., Khair, W., Sheth, S., Taher, A. T., Torti, L., Hantaweepant, C., & Rund, D. G. (2023) · British Journal of Haematology · doi:10.1111/bjh.18671 · Cited by 51
Self-citationSafety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
Gerds, A. T., Harrison, C. N., Kiladjian, J., Mesa, R. A., Vannucchi, A. M., Komrokji, R. S., Bose, P., Kremyanskaya, M., Mead, A. J., Gotlib, J. R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012939 · Cited by 52
“23,24,31 Hypertension was the most common TRAE, but cases were generally low grade and manageable, and did not result in luspa-tercept discontinuation.”
BackgroundResultYasara, N., Premawardhena, A., & Mettananda, S. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01757-w · Cited by 60
“In a recent phase 3 clinical trial in 336 patients with thalassaemia, subcutaneous luspatercept showed a 33% reduction in transfusion burden in patients with thalassaemia [104].”
BackgroundInflammation and myeloid malignancy: quenching the flame
Stubbins, R. J., Platzbecker, U., & Karsan, A. (2022) · Blood · doi:10.1182/blood.2021015162 · Cited by 49
El-Beshlawy, A. M., Dewedar, H., Hindawi, S., Alkindi, S. S. A., Tantawy, A. A. G., Yassin, M. A., & Taher, A. T. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101138 · Cited by 44
Self-citationAutologous gene therapy for hemoglobinopathies: From bench to patient’s bedside
Locatelli, F., Cavazzana, M., Frangoul, H., de la Fuente, J., Algeri, M., & Meisel, R. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.005 · Cited by 48
Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches
Bozzini, C., Busti, F., Marchi, G., Vianello, A., Cerchione, C., Martinelli, G., & Girelli, D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380358 · Cited by 53
A glutamine metabolic switch supports erythropoiesis
Lyu, J., Gu, Z., Zhang, Y., Vu, H. S., Lechauve, C., Cai, F., Cao, H., Keith, J., Brancaleoni, V., Granata, F., et al. (2024) · Science · doi:10.1126/science.adh9215 · Cited by 43
Self-citationTumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Grzywa, T. M., Justyniarska, M., Nowis, D., & Gołąb, J. (2021) · Cancers · doi:10.3390/cancers13040870 · Cited by 43
Taher, A. T., Bou‐Fakhredin, R., Kattamis, A., Viprakasit, V., & Cappellini, M. D. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1977116 · Cited by 53
Self-citationHow I treat non-transfusion-dependent β-thalassemia
Saliba, A. N., Musallam, K. M., & Taher, A. T. (2023) · Blood · doi:10.1182/blood.2023020683 · Cited by 43
Self-citationGarbowski, M., Ugidos, M., Risueño, A., Shetty, J. K., Schwickart, M., Hermine, O., Porter, J. B., Thakurta, A., & Vodala, S. (2023) · American Journal of Hematology · doi:10.1002/ajh.27102 · Cited by 38
Self-citationCOVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation
Farmakis, D. T., Giakoumis, A., Cannon, L., Angastiniotis, M., & Eleftheriou, A. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13476 · Cited by 38
Gene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 42
Novel Therapeutic Advances in β-Thalassemia
Makis, A. C., Voskaridou, E., Papassotiriou, I., & Hatzimichael, E. C. (2021) · Biology · doi:10.3390/biology10060546 · Cited by 43
“9% for the placebo, and no deaths were reported in either treatment groups [49].”
BackgroundMethodSelf-citationβ-Thalassemia: evolving treatment options beyond transfusion and iron chelation
Langer, A. L., & Esrick, E. B. (2021) · Hematology · doi:10.1182/hematology.2021000313 · Cited by 45
Non-Transfusion-Dependent Thalassemia: A Panoramic Review
Shash, H. A. (2022) · Medicina · doi:10.3390/medicina58101496 · Cited by 40
Hematopoietic Stem Cell Transplantation in Thalassemia
Algeri, M., Lodi, M., & Locatelli, F. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.009 · Cited by 39
Yasara, N., Wickramarathne, N., Mettananda, C. D., Silva, I., Hameed, N., Attanayaka, K., Rodrigo, R., Wickramasinghe, N., Perera, L., Manamperi, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06774-8 · Cited by 37
Parisi, S., Finelli, C., Fazio, A., Stefano, A. D., Mongiorgi, S., Ratti, S., Cappellini, A., Billi, A. M., Cocco, L., Follo, M. Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020827 · Cited by 39
“These findings led to a subsequent randomized, double-blind, phase III trial (BELIEVE study), in which 336 adult patients with TDT were enrolled [40].”
BackgroundThe mutual crosstalk between iron and erythropoiesis
Camaschella, C., Pagani, A., Silvestri, L., & Nai, A. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03384-y · Cited by 39
“Luspatercept that is able to decrease blood requirements is now approved for the treatment of patients with transfusion-dependent thalassemia [65].”
Metabolic regulation of erythrocyte development and disorders
Lyu, J., Ni, M., Weiss, M. J., & Xu, J. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104153 · Cited by 41
Sethakorn, N., Héninger, E., Sánchez‐de‐Diego, C., Ding, A. B., Yada, R. C., Kerr, S. C., Kosoff, D., Beebe, D. J., & Lang, J. M. (2022) · Cancers · doi:10.3390/cancers14030757 · Cited by 34
Challenges in chronic transfusion for patients with thalassemia
Lal, A. (2020) · Hematology · doi:10.1182/hematology.2020000102 · Cited by 39
Self-citationBreaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 34
Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major
Santarone, S., Angelini, S., Natale, A., Vaddinelli, D., Spadano, R., Casciani, P., Papola, F., Lembo, E. D., Iannetti, G., & Bartolomeo, P. D. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01786-4 · Cited by 30
“A new medical therapy based on the use of luspatercept (formerly ACE-536) has been recently described [2, 3].”
BackgroundNovel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders
Pinto, V. M., Mazzi, F., & Franceschi, L. D. (2024) · Blood · doi:10.1182/blood.2023022193 · Cited by 33
Cappellini, M. D., Viprakasit, V., Georgiev, P., Coates, T. D., Origa, R., Khélif, A., Liew, H.-K., Tantiworawit, A., Chew, L.-P., Khalil, A., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00376-4 · Cited by 30
Self-citationBeta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation
Chauhan, W., Shoaib, S., Fatma, R., Zaka‐ur‐Rab, Z., & Afzal, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15343 · Cited by 32
“(TDT), the Food and Drug Administration approved it in September 2020.(64)”
BackgroundFerraresi, M., Panzieri, D. L., Leoni, S., Cappellini, M. D., Kattamis, A., & Motta, I. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04900-w · Cited by 38
“The results of the phase III BELIEVE trial [23] led to the approval of luspatercept for the treatment of anemia in adult patients with TDT by the Food and Drug Administration (FDA) [24] and European Medicines Agency (EMA) [25, 26].”
BackgroundSelf-citationCappellini, M. D., Russo, R., Andolfo, I., & Iolascon, A. (2020) · Hematology · doi:10.1182/hematology.2020000158 · Cited by 31
Self-citationHemoglobin Bart’s hydrops fetalis: charting the past and envisioning the future
Amid, A., Liu, S., Babbs, C., & Higgs, D. R. (2024) · Blood · doi:10.1182/blood.2023023692 · Cited by 28
Premawardhena, A., Ediriweera, D. S., Sabouhanian, A., Allen, A., Rees, D. C., de Silva, S., Perera, W., Katugaha, N., Arambepola, M., YAMASHITA, R. C., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00446-0 · Cited by 26
Cardiac complications in thalassemia throughout the lifespan: Victories and challenges
Wood, J. C. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15078 · Cited by 28
Mulas, O., Mola, B., Caocci, G., & Nasa, G. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040907 · Cited by 23
“such as luspatercept, an inhibitor of ineffective erythropoiesis that acts as an activin IIB receptor-ligand trap [7].”
BackgroundSustainable Energy Production in Smart Cities
Salama, R., & Al-Turjman, F. M. (2023) · Sustainability · doi:10.3390/su152216052 · Cited by 24
Innovative Treatments for Rare Anemias
Cappellini, M. D., Marcon, A., Fattizzo, B., & Motta, I. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000576 · Cited by 24
Self-citationMyostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification
Esposito, P. B., Verzola, D., Picciotto, D., Cipriani, L., Viazzi, F. C., & Garibotto, G. (2021) · Cells · doi:10.3390/cells10082070 · Cited by 23
“B-thalassemia Phase 2 [131] Phase 3 [132] Open-label RCT 64 336 Reduction >20% in transfusion burden in 81% of cases Reduction >33% in transfusion burden in 70.”
BackgroundLong-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
Piga, A. G., Longo, F., Gamberini, M. R., Voskaridou, E., Ricchi, P., Caruso, V., Pietrangelo, A., Zhang, X., Shetty, J. K., Attie, K. M., et al. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221134404 · Cited by 23
Self-citationvan Dijk, M. J., de Wilde, J. R. A., Bartels, M., Kuo, K. H. M., Glenthøj, A. B., Rab, M. A. E., van Beers, E. J., & van Wijk, R. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101103 · Cited by 23
Self-citationManagement of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia
Sheth, S., Taher, A. T., Coates, T. D., Kattamis, A., & Cappellini, M. D. (2023) · British Journal of Haematology · doi:10.1111/bjh.18801 · Cited by 21
Self-citationHurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia
Thuret, I., Ruggeri, A., Angelucci, E., & Chabannon, C. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac007 · Cited by 25
The congenital dyserythropoieitic anemias: genetics and pathophysiology.
King, R., Gallagher, P. J., & Khoriaty, R. N. (2022) · PubMed · doi:10.1097/moh.0000000000000697 · Cited by 13
Hatzimichael, E. C., Timotheatou, D., Koumpis, E., Benetatos, L., & Makis, A. C. (2022) · Diseases · doi:10.3390/diseases10040085 · Cited by 24
Guerra, A., Parhiz, H., & Rivella, S. (2023) · Haematologica · doi:10.3324/haematol.2023.283057 · Cited by 21
Corbacioglu, S., Frangoul, H., Locatelli, F., Hobbs, W., & Walters, M. C. (2023) · American Journal of Hematology · doi:10.1002/ajh.27166 · Cited by 20
Abnormal regulation of microRNAs and related genes in pediatric β‐thalassemia
Wang, H., Chen, M., Xu, S., Pan, Y., Zhang, Y., Huang, H., & Xu, L. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23945 · Cited by 28
Genetic and Epigenetic Therapies for β-Thalassaemia by Altering the Expression of α-Globin Gene
Mettananda, S. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.752278 · Cited by 20
Luspatercept for β-thalassemia: beyond red blood cell transfusions
Taher, A. T., & Cappellini, M. D. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1968825 · Cited by 19
“25 mg/kg) or placebo every 3 weeks for ≥48 weeks (Figure 3) [59].”
BackgroundMethodResultInfluentialSelf-citationPremawardhena, A., Perera, C., Wijethilaka, M. N., Wanasinghe, S. K., Rajakaruna, R., Samarasinghe, R. A. N. K. K., Williams, S., & Mettananda, S. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-077342 · Cited by 19
“17 18 22 Despite these advances, many patients with transfusion-dependent β -thalassaemia, those who live in low-income and middle-income countries in particular, are managed medically with regular blood transfusions and iron chelation.”
BackgroundBhurani, D., Kapoor, J., Yadav, N., Khushoo, V. K., Agrawal, N., Ahmed, R., Arora, J. S., & Mehta, P. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04501-3 · Cited by 18
“Recently, luspatercept (a recombinant fusion protein that binds to transforming growth factor B ligands) has been approved for β-TDT on the basis of a randomized, phase 3 trial where the drug had shown significant reduction in transfusion burden with few adverse events [10].”
MethodNovel therapies in β‐thalassaemia
Grech, L., Borg, K., & Borg, J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14918 · Cited by 19
Luspatercept for transfusion-dependent β-thalassemia: time to get real
Musallam, K. M., Sheth, S., Cappellini, M. D., Kattamis, A., Kuo, K. H. M., & Taher, A. T. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231195594 · Cited by 18
Self-citationBarbero, U., Ajassa, M., Gaglioti, C. M., Piga, A. G., Ferrero, G. B., & Longo, F. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9010003 · Cited by 17
“cardiovascular risk scores may appear low [22].”
Self-citationThe Roles of Mitophagy and Autophagy in Ineffective Erythropoiesis in β-Thalassemia
Chaichompoo, P., Svasti, S., & Smith, D. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810811 · Cited by 22
Bayesian Strategies in Rare Diseases
Garczarek, U., Muehlemann, N., Richard, F., Yajnik, P., & Russek‐Cohen, E. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00485-y · Cited by 19
“For example, in the BELIEVE study, out of 112 patients randomized to the control arm, five patients (4.5”
MethodInfluentialAnemia and iron overload as prognostic markers of outcomes in β-thalassemia
Musallam, K. M., Sheth, S., Cappellini, M. D., Forni, G. L., Maggio, A., & Taher, A. T. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383420 · Cited by 19
“Response to disease modifying therapies such as luspatercept has also been shown to be modified (delayed) in TDT patients with a β 0 /β 0 vs non-β 0 /β 0 genotype [20,21].”
Self-citationWang, Z., Zhang, Z., Lyu, Z., Xing, T., Mi, L., Shen, M.-Z., Li, C., Zhang, X., Chen, D., Wang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217290 · Cited by 17
Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat
Bou‐Fakhredin, R., Cappellini, M. D., Taher, A. T., & Franceschi, L. D. (2024) · American Journal of Hematology · doi:10.1002/ajh.27500 · Cited by 18
Self-citationCardiac injury caused by iron overload in thalassemia
Fu, C., & Yang, X. Y. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1514722 · Cited by 20
Primary HBB gene mutation severity and long‐term outcomes in a global cohort of β‐thalassaemia
Musallam, K. M., Vitrano, A., Meloni, A., Pollina, S. A., Marco, V. D., Ansari, S. H., Filosa, A., Ricchi, P., Ceci, A., Daar, S., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17897 · Cited by 16
Self-citationGene Therapy for Hemoglobinopathies
Lidonnici, M. R., Scaramuzza, S., & Ferrari, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.138 · Cited by 18
β-Thalassemia gene editing therapy: Advancements and difficulties
Hu, J., Zhong, Y., Xu, P., Xin, L., Zhu, X., Jiang, X., Gao, W., Yang, B., & Chen, Y. (2024) · Medicine · doi:10.1097/md.0000000000038036 · Cited by 24
Emerging therapies in β-thalassemia: toward a new era in management
Bou‐Fakhredin, R., Tabbikha, R., Daadaa, H., & Taher, A. T. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1752180 · Cited by 20
“or placebo subcutaneously every 21 days for at least 48 weeks [81].”
BackgroundSelf-citationManagement of non‐transfusion‐dependent β‐thalassemia ( NTDT ): The next 5 years
Musallam, K. M., Rivella, S., & Taher, A. T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26055 · Cited by 20
Self-citationTargeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease
Aprile, A., Sighinolfi, S., Raggi, L., & Ferrari, G. (2022) · Pharmaceuticals · doi:10.3390/ph15050592 · Cited by 19
“Luspatercept binds to transforming growth factor (TGF) β superfamily ligands, enhances late-stage erythropoiesis by blocking SMAD2/3 signaling, and reduces RBC transfusion requirements in TDT with a proportion of patients achieving transfusion independence [40].”
BackgroundSiciliano, A., D’Alessandro, A., Mattè, A., Bisello, G., Bertoldi, M., Dzieciątkowska, M., Argabright, A., Huot, R. P., Riccardi, V., Mattarei, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013591 · Cited by 15
Emergent treatments for β-thalassemia and orphan drug legislations
Costa, E., Cappellini, M. D., Rivella, S., Chilin, A., Alessi, E., Riccaboni, M., Leufkens, H. G. M., & Luzzatto, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103342 · Cited by 18
Self-citation
Metadata
- Authors
- Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., Perrotta, S., Khelif, A., Lal, A., Kattamis, A., Vlachaki, E., Origa, R., Aydinok, Y., Bejaoui, M., Ho, P. J., Chew, L.-P., Bee, P.-C., Lim, S.-M., Lu, M.-Y., Tantiworawit, A., Ganeva, P., Gercheva, L., Shah, F., Neufeld, E. J., Thompson, A., Laadem, A., Shetty, J. K., Zou, J., Zhang, J., Miteva, D., Zinger, T., Linde, P. G., Sherman, M. L., Hermine, O., Porter, J., & Piga, A.
- Affiliations
- University of Milan (IT)
- Siriraj Hospital (TH)
- University Health Network (CA)
- University of Southern California (US)
- From the Department of Clinical Sciences and Community, University of Milan, IRCCS Ca’ Granda Foundation Maggiore Policlinico Hospital, Milan (M.D.C.), Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, E.O. Ospedali Galliera, Genoa (G.L.F.), Ospedale Pediatrico Microcitemico A. Cao, Azienda Ospedaliera G. Brotzu, Cagliari (R.O.), Ematologia e Oncologia Pediatrica, Università della Campania L. Vanvitelli, Caserta (S.P.), and the Department of Clinical and Biological...
- University of California, San Francisco (US)
- The University of Sydney (AU)
- University Malaya Medical Centre (MY)
- St. Jude Children's Research Hospital (US)
- Lurie Children's Hospital (US)
- Hôpital Necker-Enfants Malades (FR)
- University College London Hospitals NHS Foundation Trust (GB)
- ORCID
- Cappellini, M. Domenica
- Viprakasit, Vip
- Taher, Ali T.
- Georgiev, Pencho
- Kuo, Kevin H.M.
- Coates, Thomas
- Voskaridou, Ersi
- Perrotta, Silverio
- Lal, Ashutosh
- Kattamis, Antonis
- Vlachaki, Efthymia
- Origa, Raffaella
- Ho, P. Joy
- Bee, Ping-Chong
- Lu, Meng-Yao
- Tantiworawit, Adisak
- Gercheva, Liana
- Shah, Farrukh
- Neufeld, Ellis J.
- Thompson, Alexis
- Laadem, Abderrahmane
- Shetty, Jeevan K.
- Sherman, Matthew L.
- Hermine, Olivier
- Piga, Antonio
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-03-26
- Volume
- 382
- Issue
- 13
- Pages
- 1219-1231
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3014005795
- Cited by
- 332
- References
- 28
- Citations by year
- 2026: 51 · 2025: 48 · 2024: 57 · 2023: 49 · 2022: 54 · 2021: 52 · 2020: 21
- FWCI
- 22.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Acceleron Pharma
- Celgene
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- transfusion-dependent beta-thalassemia, transfusion burden, erythroid maturation, recombinant fusion protein, serum ferritin, iron overload, adverse events, hyperuricemia, hypertension, bone pain, joint pain, dizziness, best supportive care
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Ferritins, Hematinics, Humans, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins, Splenectomy, Odds Ratio, Least-Squares Analysis, beta-Thalassemia, Erythrocyte Transfusion, Activin Receptors, Type II, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.